Albert Labs Scientific and Clinical Advisory Boards will support the company’s efforts to develop its proprietary psychedelics-based medicine and conduct accelerated studies on UK patients suffering from cancer-related anxiety.
JUNE 24 , 2021 – VANCOUVER, BRITISH COLUMBIA,
Albert Labs (or the “Company”), an innovative psychedelic drug developer focused on accelerating access to approved psychedelics-based medicines for patients with urgent and unmet needs continues to bolster its two Advisory Boards announcing today the appointment of more renowned experts. The additions to the Clinical Advisory Board, chaired by Professor Jo Neill, bring expertise in psychology, psychiatry, palliative care and oncology. This multidisciplinary team will provide unrivalled guidance, helping Albert Labs progress through its accelerated Real-World Evidence (RWE) trial programme commencing in the UK later this year. To hear more about the advisory boards and listen to Professor Jo Neill click here.
Joining Parminder Singh, and further reinforcing the Albert Labs Scientific Advisory Board, are experts in IP protection and development of novel manufacturing technologies through natural cultivation, extraction, formulation and delivery. This expertise will be instrumental to Albert Labs developing and protecting its pharma grade natural psilocybin-based medicine.
The Clinical Advisory Board includes:
Professor Jo Neill, BSc Pharmacology, PhD in Psychopharmacology.
Jo is a Professor of Psychopharmacology at the University of Manchester. She is Chair of the Medical Psychedelics Working Group for Drug Science, a scientific advisor for Heroic Hearts UK, the Conservative Drug Policy Reform Group, Psychedelic Experience and Beckley Psytech. She is co-founder of b-neuro, a University-based Contract Research Organisation (CRO) developing new treatments for mental illness through animal models. Jo is past President of the British Association for Psychopharmacology.
Dr. Sara Tai, BA(Hons), MSc, D.ClinPsy, Cpsychol/Impact
Dr Sara Tai is a Senior Lecturer in Clinical Psychology at the University of Manchester and Consultant Clinical Psychologist at Cheadle Royal Hospital and Greater Manchester West Mental Health NHS Foundation Trust. Sara is an experienced practitioner, trainer, and supervisor of transdiagnostic approaches for working with people with serious mental health problems and their families; providing one-to-one interventions, group interventions, and family work. She has an international reputation as a trainer in CBT and has published widely in this area, including the book “A principles-based approach to counselling and psychotherapy”.
Dr. Sara Tookey, DClinPsy, PhD, MA, HCPC
Dr. Tookey is a Clinical Psychologist, HCPC registered and BPS Chartered Psychologist. She holds a PhD in Psychology with a specialism in Psycho-oncology, a doctorate in Clinical Psychology and an MA in Existential Phenomenological Psychology. She is an experienced qualitative researcher and Qualitative Methods Lecturer. Sara specialises in integrative therapies, incorporating approaches of Cognitive Behavioral Therapy (CBT), Existential Therapy, Systemic, psycho-dynamically informed, Acceptance and Commitment Therapy (ACT), Compassion-focused therapy (CFT).
Professor Emeritus Sam Ahmedzai, FRCP, FRCPGlas, FFPMRCoA
Professor Sam Ahmedzai is the National Institute for Health Research (NIHR) National Specialty Lead for Cancer: Supportive Care and Community-Based Research. He was a professor of supportive and palliative care at the University of Sheffield for 20 years and also served as a clinical expert adviser for NICE NHS Evidence; as a member of the council of the British Pain Society.
Professor Saoirse O’Sullivan, BA Mod Hons, PhD
Saoirse is a Professor of Pharmacology in the Faculty of Medicine & Health Sciences at the University of Nottingham. Dr. O’Sullivan is a leading researcher in the field of cannabinoids and has published numerous papers on the role of cannabinoid receptors in health and disease. Dr. O’Sullivan brings cross-domain expertise surrounding the Pharmacology of natural medicines.
The Scientific Advisory Board includes:
Parminder Singh, IP protection, Licensing & Patents
Parminder Singh is a seasoned executive with more than 30 years of technical, operations and international business in both corporate and entrepreneurial environments. He has worked in undercapitalized start-ups through to Fortune 100 multinational corporations. His industry experience includes software & product development, intellectual property, with particular experience with medical devices, and satellite systems.
Dr. Naeem Khan, D.Chem, EU-GMP Expertise
Naeem holds a PhD in Chemistry and has over 60 years of experience in industrial pharmaceutical production. Naeem provides notable competence for EU GMP certification, development of Quality Management systems, validation of manufacturing processes and analytical methods, supplier approval and Pharmacovigilance.
Denzil Phillips, Medicinal Plant Licencing, Product Registration and Compliance.
Denzil has worked for over 30 years in the field of botanicals and natural productions particularly in Africa, Asia, and the Caribbean. Denzil specializes in the design and implementation of projects in the field of medicinal plants and related botanical products. Providing advice on regulations and certifications for new plant-based medicines, Denzil also serves as an associate consultant at Global Regulatory Services, one of the leading regulatory consultancies in Europe.
The Advisory Boards announcement strengthens the strategic direction and aligns with the company’s mission to accelerate access to psychedelics-based medicines for patients with urgent and unmet needs.
Business of Albert Labs Inc.
Listen to Albert Labs’ Chief Medical Officer, Dr. Malcolm Barratt-Johnson introduce Albert Labs and their mission here.
Albert Labs is the first psychedelic company to leverage Real World Evidence (RWE) Studies to accelerate access to approved psychedelic medicines in hospital settings across the UK and Europe to treat mental health indications with urgent and high unmet needs. Albert will own the wide dataset collected in the studies to develop an IP stack around unique formulation and delivery mechanisms of its approved psychedelics drug therapy.
A laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies. Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring proprietary natural psilocybin-assisted therapy to the UK and Europe before expanding globally. Albert Labs is going through an RTO with a listing expected soon. More details can be found in our previous news release.
Albert Labs has submitted applications for psychedelic research and a dealer’s license which will allow the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline in its lab in Burnaby, BC Canada. These Health Canada licenses will also allow the company to export, test, and conduct R&D on these controlled substances.
Watch a short “About Albert Labs” video and hear more of the investment opportunity here.
ON BEHALF OF THE BOARD OF DIRECTORS
Albert Labs Inc.
Dr. Michael Raymont, CEO
For further information please contact:
Tel: +44 7828 008237
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate.
The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements.
Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise unless required by the applicable securities laws.